Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Ozempic being a household name, GLP-1 receptor agonists (GLP-1RAs), a class of medications have garnered significant ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...